Cryptococcosis Associated With Biologic Therapy: A Narrative Review
- Author(s)
- Li, X; Paccoud, O; Chan, KH; Yuen, KY; Manchon, R; Lanternier, F; Slavin, MA; van de Veerdonk, FL; Bicanic, T; Lortholary, O;
- Details
- Publication Year 2024-07,Volume 11,Issue #7,Page ofae316
- Journal Title
- Open Forum Infectious Diseases
- Publication Type
- Review
- Abstract
- Cryptococcus is an opportunistic fungal pathogen that can cause disseminated infection with predominant central nervous system involvement in patients with compromised immunity. Biologics are increasingly used in the treatment of neoplasms and autoimmune/inflammatory conditions and the prevention of transplant rejection, which may affect human defense mechanisms against cryptococcosis. In this review, we comprehensively investigate the association between cryptococcosis and various biologics, highlighting their risks of infection, clinical manifestations, and clinical outcomes. Clinicians should remain vigilant for the risk of cryptococcosis in patients receiving biologics that affect the Th1/macrophage activation pathways, such as tumor necrosis factor α antagonists, Bruton tyrosine kinase inhibitors, fingolimod, JAK/STAT inhibitors (Janus kinase/signal transducer and activator of transcription), and monoclonal antibody against CD52. Other risk factors-such as age, underlying condition, and concurrent immunosuppressants, especially corticosteroids-should also be taken into account during risk stratification.
- Publisher
- Oxford University Press
- Keywords
- autoimmune diseases; biologics; cryptococcosis; hematology; transplant
- Department(s)
- Infectious Diseases
- Publisher's Version
- https://doi.org/10.1093/ofid/ofae316
- Open Access at Publisher's Site
https://doi.org/10.1093/ofid/ofae316- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-08-06 05:29:23
Last Modified: 2024-08-06 05:31:19